Addex Therapeutics (ADXN) EBITDA Margin (2019 - 2025)
Addex Therapeutics (ADXN) posted EBITDA Margin of 314218.95% for Q4 2025, down 13315.94% sequentially from 2342.13% in Q3 2025, and down 13152664.0% YoY from N/an in Q4 2024.
Addex Therapeutics (ADXN) EBITDA Margin (2019 - 2025) Analysis & Trends
Addex Therapeutics has reported EBITDA Margin for 7 years, with the latest figure at 314218.95% in Q4 2025.
- Quarterly EBITDA Margin fell 13152664.0% year-over-year to 314218.95% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 8688.09% (down 743263.0% YoY) and the FY2025 annual result came in at 9390.76%, down 870894.0% from the prior year.
- EBITDA Margin eased to 314218.95% in Q4 2025 per ADXN's latest filing, from 2342.13% in the prior quarter.
- Over five years, EBITDA Margin peaked at 62.8% in Q2 2023 and troughed at 314218.95% in Q4 2025.
- A 5-year average of 28665.27% and a median of 898.96% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2024: EBITDA Margin surged 1089379 bps in 2021, then sank 18123060 bps in 2024.
- Over 5 years, EBITDA Margin stood at 491.79% in 2021, then sank by 604 bps to 3463.7% in 2022, then jumped by 58 bps to 1461.7% in 2023, then slumped by 12399 bps to 182692.31% in 2024, then tumbled by 72 bps to 314218.95% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 314218.95%, 2342.13%, and 182692.31% for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Addex Therapeutics | 515.38 Mn | 515.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -314,218.95% |
| Sep 30, 2025 | -2,342.13% |
| Dec 31, 2024 | -182,692.31% |
| Sep 30, 2024 | -1,155.71% |
| Jun 30, 2024 | -780.13% |
| Mar 31, 2024 | -337.54% |
| Dec 31, 2023 | -1,461.70% |
| Sep 30, 2023 | -228.61% |
| Jun 30, 2023 | -62.80% |
| Mar 31, 2023 | -73.40% |
| Dec 31, 2022 | -3,463.70% |
| Sep 30, 2022 | -1,017.78% |
| Jun 30, 2022 | -3,868.04% |
| Mar 31, 2022 | -2,429.04% |
| Dec 31, 2021 | -491.79% |
| Sep 30, 2021 | -524.31% |
| Jun 30, 2021 | -454.03% |
| Mar 31, 2021 | -372.89% |
| Dec 31, 2020 | -315.62% |
| Sep 30, 2020 | -11,418.10% |